Related Experiment Video
Updated: Aug 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Reducing the risk of coronary heart disease via lipid reduction
1University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th & Market Streets, Philadelphia, PA 19104, USA. kspratt@uphs.upenn.edu
Abstract:
Elevated low-density lipoprotein cholesterol (LDL-C) is closely associated with an increased risk of cardiovascular morbidity and mortality. Results from numerous well-designed clinical trials indicate that interventions designed to modify lipid levels significantly reduce the risk of coronary heart disease (CHD), particularly in patients at highest risk. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines recommend matching the intensity of lipid-lowering therapy to the patient's risk of CHD. However, despite the existence of evidence-based treatment guidelines and the availability of many safe and effective lipid-modifying modes of therapy, optimal CHD risk reduction rarely is achieved.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease I: Introduction
Coronary Artery Disease V: Interprofessional Care
Lipids: Dietary Sources and Requirements